The cytokine profile of menstrual blood

Introduction

The menstrual cycle is regulated by a complex interplay between endometrial epithelial cells, endothelial cells, immune cells, and sex hormones. To communicate, cells secrete cytokines that have multiple and diverse effects on recipient cells. Knowledge of how these cells interact in the uterus is insufficient. Menstrual blood is easily accessible and provides a source to study menstrual cycle physiology. This study aimed to determine the cytokine profile in menstrual blood plasma and investigate the differences in cytokine profiles between menstrual and peripheral blood plasma. Several previous studies indicate an improved chance of embryo implantation after endometrial scratching. Consequently, our secondary aim was to compare the menstrual blood cytokine profile before and after luteal phase endometrial scratching.

Material and methods

Nineteen healthy donors collected menstrual blood for the first 24 hours of menstruation in two sequential cycles. Matched peripheral blood was taken at the same time. An endometrial biopsy was performed at cycle day 7‐9 post ovulation in between the two collection times. A Luminex multiplex assay was performed in one batch analyzing a predetermined group of cytokines in plasma.

Results

Peripheral blood plasma and menstrual blood plasma showed substantial significant differences in cytokine profile. In menstrual blood plasma, C5/C5a, interleukin‐6 (IL‐6), IL‐1β, and CXCL8 were detected in high concentrations, whereas IL‐2, IL‐12p70, XCL1/Lymphotactin, and interferon‐γ were low. The most pronounced median differences between menstrual and peripheral blood plasma were found for IL‐6, IL‐1β, and CXCL8. The cytokine profiles of menstrual blood plasma were similar between the individual donors and did not differ over two subsequent cycles. None of the cytokines analyzed in menstrual blood plasma differed significantly before or after luteal phase endometrial scratching (P < .01).

Conclusions

Our results demonstrate that the menstrual blood cytokine profile is distinctly different from peripheral blood plasma and that the inter‐individual difference in menstrual blood cytokine profile in healthy donors is limited and stable over time. The small injury caused by an endometrial biopsy does not change the cytokine profile in the subsequent menstrual cycle. Our study provides new insights into menstrual cycle physiology.

Intravaginally applied oxytocin improves post-menopausal vaginal atrophy

Objective

To explore the efficacy of local oxytocin for the treatment of post-menopausal vaginal atrophy.

Design

Double-blinded randomised controlled trial.

Setting

Healthy post-menopausal women in Stockholm, Sweden.

Participants

Sixty four post-menopausal women between February and June 2012 at the Karolinska University Hospital Huddinge/Sweden.

Main outcome measures

The efficacy of oxytocin for treatment of vaginal atrophy after seven weeks and cytological evaluation.

Results

The percentage of superficial cells in the vaginal smears and the maturation values were significantly increased after seven weeks of treatment with vagitocin 400 IU (p = 0.0288 and p = 0.0002, respectively). The vaginal pH decreased significantly after seven weeks of treatment with vagitocin 100 IU (p = 0.02). The scores of vaginal atrophy, according to the histological evaluation, were significantly reduced after administration of vagitocin 100 IU (p = 0.03). The thickness of the endometrium did not differ between the treatment and placebo groups after seven weeks of treatment. The symptom experienced as the most bothersome was significantly reduced after seven weeks of treatment in the women receiving vagitocin 400 IU compared to women in the placebo group (p = 0.0089).

Conclusions

Treatment with intravaginally applied oxytocin could be an alternative to local estrogen treatment in women with post-menopausal vaginal atrophy.